Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 39 (TRAV39) encodes the V (variable) region of the alpha chain of the T cell receptor (TCR), a protein complex expressed on the surface of T lymphocytes that is essential for antigen recognition and initiating T cell-mediated adaptive immune responses[1][7]. TRAV39 is one of many variable (V) gene segments that participate in somatic recombination during T cell development, contributing to the diversity of the T cell receptor repertoire[1][2][4]. The alpha-beta TCR recognises peptide-MHC complexes presented by antigen-presenting cells, triggering intracellular signaling and T-cell responses[1][3][7]. The gene segment itself does not act as a direct therapeutic target; rather, it forms part of the TCR complex whose broad function is critical in immunity[1][3][7]. TRAV39 is a variable segment; it is not a full receptor on its own nor an independent drug target. No drugs are currently known to interact with this specific gene segment, and it is not used as a clinical biomarker or a therapeutic target. There are no unique safety concerns tied to TRAV39, as its role is as a genomic element involved in TCR gene rearrangement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 39 (TRAV39).